Phase I Study of Ramucirumab in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
Price : $35 *
At a glance
- Drugs Ramucirumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly
- 20 Apr 2016 Results assessing the safety profile and pharmacokinetics of ramucirumab presented at the 107th Annual Meeting of the American Association for Cancer Research
- 19 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.